Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Avet-Loiseau, T. Facon, B. Grosbois, F. Magrangeas, M. Rapp, J. Harousseau, S. Minvielle, R. Bataille (2002)
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.Blood, 99 6
P. Finelli, S. Fabris, S. Zagano, L. Baldini, D. Intini, L. Nobili, L. Lombardi, A. Maiolo, A. Neri (1999)
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.Blood, 94 2
C. Powers, S. Mcleskey, A. Wellstein (2000)
Fibroblast growth factors, their receptors and signaling.Endocrine-related cancer, 7 3
Jing Chen, Benjamin Lee, I. Williams, J. Kutok, C. Mitsiades, Nicole Duclos, Sarah Cohen, Jennifer Adelsperger, R. Okabe, Allison Coburn, Sandra Moore, B. Huntly, D. Fabbro, K. Anderson, J. Griffin, D. Gilliland (2005)
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesOncogene, 24
P. Bergsagel, W. Kuehl (2003)
Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myelomaImmunological Reviews, 194
M. Gertz, M. Lacy, A. Dispenzieri, P. Greipp, M. Litzow, K. Henderson, S. Wier, G. Ahmann, R. Fonseca (2005)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.Blood, 106 8
D. Cappellen, C. Oliveira, David Ricol, S. Medina, J. Bourdin, X. Sastre-Garau, D. Chopin, J. Thiery, F. Radvanyi (1999)
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomasNature Genetics, 23
D. Intini, L. Baldini, S. Fabris, L. Lombardi, G. Ciceri, A. Maiolo, A. Neri (2001)
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)British Journal of Haematology, 114
M. Chesi, E. Nardini, Robert Lim, Kerrington Smith, W. Kuehl, P. Bergsagel (1998)
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.Blood, 92 9
S. Trudel, Zhi Li, E. Wei, M. Wiesmann, Hong Chang, Christine Chen, D. Reece, C. Heise, A. Stewart (2004)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.Blood, 105 7
S. Soverini, C. Terragna, N. Testoni, D. Ruggeri, P. Tosi, E. Zamagni, C. Cellini, M. Cavo, M. Baccarani, S. Tura, G. Martinelli (2002)
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.Haematologica, 87 10
R. Richelda, D. Ronchetti, Luca Baldini, L. Cro, L. Viggiano, R. Marzella, Mariano Rocchi, Takemi Otsuki, L. Lombardi, A. Maiolo, A. Neri (1997)
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.Blood, 90 10
Xiaohua Xin, T. Abrams, P. Hollenbach, K. Rendahl, Yan Tang, Y. Oei, M. Embry, D. Swinarski, E. Garrett, N. Pryer, S. Trudel, B. Jallal, D. Mendel, C. Heise (2006)
CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in MiceClinical Cancer Research, 12
S. Trudel, A. Stewart, E. Rom, E. Wei, Zhi Li, Sarit Kotzer, I. Chumakov, Y. Singer, Hong Chang, S. Liang, A. Yayon (2006)
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.Blood, 107 10
C. Chang, S. McClintock, R. Cleveland, Trent Trzpuc, D. Vesole, B. Logan, A. Kajdacsy-Balla, S. Perkins (2004)
Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell LymphomaThe American Journal of Surgical Pathology, 28
I. Mason (2003)
Fibroblast growth factorsCurrent Biology, 13
P. Bergsagel, W. Kuehl (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 26
M. Chesi, E. Nardini, L. Brents, E. Schröck, T. Ried, W. Kuehl, P. Bergsagel (1997)
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nature Genetics, 16
Hong Chang, A. Stewart, X. Qi, Zhi Li, Qi‐long Yi, S. Trudel (2005)
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.Blood, 106 1
J. Keats, T. Reiman, C. Maxwell, B. Taylor, L. Larratt, M. Mant, A. Belch, L. Pilarski (2003)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.Blood, 101 4
C. L'hôte, M. Knowles (2005)
Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.Experimental cell research, 304 2
R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. Bergsagel, M. Chesi, F. Davies, J. Drach, P. Greipp, I. Kirsch, W. Kuehl, Jesús Hernández, S. Minvielle, L. Pilarski, J. Shaughnessy, A. Stewart, H. Avet‐Loiseau, H. Avet‐Loiseau (2004)
Genetics and Cytogenetics of Multiple MyelomaCancer Research, 64
M. Passos-Bueno, W. Wilcox, E. Jabs, A. Sertié, L. Alonso, H. Kitoh (1999)
Clinical spectrum of fibroblast growth factor receptor mutationsHuman Mutation, 14
J. Cook, Marybeth Hartke, J. Pettay, R. Tubbs (2006)
Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence.The Journal of molecular diagnostics : JMD, 8 4
J. Keats, T. Reiman, A. Belch, L. Pilarski (2006)
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myelomaLeukemia & Lymphoma, 47
T. Ratliff (2005)
Cell Responses to FGFR3 Signaling: Growth, Differentiation and ApoptosisThe Journal of Urology, 174
M. Chesi, P. Bergsagel, W. Kuehl (2002)
The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.Current opinion in hematology, 9 4
D. Khnykin, G. Trøen, J. Berner, J. Delabie (2006)
The expression of fibroblast growth factors and their receptors in Hodgkin's lymphomaThe Journal of Pathology, 208
Obiageli Onwuazor, X. Wen, D. Wang, L. Zhuang, E. Masih-Khan, Jaimie Claudio, B. Barlogie, J. Shaughnessy, A. Stewart (2003)
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.Blood, 102 2
D. Tomlinson, O. Baldo, P. Harnden, M. Knowles (2007)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerThe Journal of Pathology, 213
Zhihua Li, Zhihua Li, Yuan Zhu, Yuan Zhu, Elizabeth Plowright, Elizabeth Plowright, P. Bergsagel, P. Bergsagel, M. Chesi, M. Chesi, Bruce Patterson, Bruce Patterson, T. Hawley, T. Hawley, Robert Hawley, Robert Hawley, A. Stewart, A. Stewart (2001)
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.Blood, 97 8
Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas Andrew Larson, DO and James R. Cook, MD, PhD acquired activating mutations of FGFR3 have been Abstract: Fibroblast growth factor receptor 3 (FGFR3) protein described in malignancies such as cervical or bladder 3,5 is aberrantly expressed in approximately 15% of cases of plasma carcinomas. Aberrant expression of FGFR3 also cell myeloma as a result of t(4;14)(p16.3;q32), and FGFR3 occurs in approximately 15% to 20% of plasma cell 6–9 expression in myeloma is associated with an adverse prognosis. myeloma, generally as a result of t(4;14)(p16.3;q32). Novel, recently developed therapeutic agents that target the Because cases of myeloma with FGFR3 overexpression 10,11 FGFR3 pathway are currently in clinical trials for myeloma. are associated with an unfavorable prognosis, novel Although extensively studied in plasma cell neoplasms, there is therapeutic agents have been developed which specifically little information in the literature regarding FGFR3 expression target FGFR3 signaling or expression and show in vitro 12–15 in malignant lymphomas, and it is unclear whether lymphoma activity against FGFR3-positive myeloma cells. patients may also benefit from anti-FGFR3 therapy. We, Although many studies have examined FGFR3 10,11,16 therefore,
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Jul 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.